These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8011244)

  • 1. Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain.
    Jansson M; Wahren B; Albert J; Scarlatti G; Franzén L; Kataaha PK; Katabira E; Mubiro F; Wigzell H; Rossi P
    AIDS; 1994 Apr; 8(4):413-21. PubMed ID: 8011244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.
    Riley JP; Pestano GA; Hosford K; Francis C; Xie JM; Mugyenyi P; Kataaha P; Katongole-Mbidde E; Anokbonggo WW; Guyden J
    Arch Virol; 1995; 140(8):1393-404. PubMed ID: 7544970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
    Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC
    J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T; Kurth R; Norley S
    J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater diversity of the HIV-1 V3 neutralization domain in Tanzania compared with The Netherlands: serological and genetic analysis.
    Zwart G; Wolfs TF; Bookelman R; Hartman S; Bakker M; Boucher CA; Kuiken C; Goudsmit J
    AIDS; 1993 Apr; 7(4):467-74. PubMed ID: 8507412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D.
    Pestano GA; Hosford KS; Spira AI; Riley J; Xie JM; Sewankambo N; Brown L; Ho DD; Boto WM
    AIDS Res Hum Retroviruses; 1995 May; 11(5):589-96. PubMed ID: 7576915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
    Hunt JC; Golden AM; Lund JK; Gürtler LG; Zekeng L; Obiang J; Kaptué L; Hampl H; Vallari A; Devare SG
    AIDS Res Hum Retroviruses; 1997 Aug; 13(12):995-1005. PubMed ID: 9264286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization.
    Cheingsong-Popov R; Lister S; Callow D; Kaleebu P; Beddows S; Weber J
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1379-86. PubMed ID: 7888191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120.
    Baillou A; Brand D; Denis F; M'Boup S; Chout R; Goudeau A; Barin F
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1209-15. PubMed ID: 7511395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
    Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
    AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania.
    Lukashov VV; Cornelissen MT; Goudsmit J; Papuashvilli MN; Rytik PG; Khaitov RM; Karamov EV; de Wolf F
    AIDS; 1995 May; 9(5):435-9. PubMed ID: 7639968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.
    Zwart G; Back NK; Ramautarsing C; Valk M; van der Hoek L; Goudsmit J
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):245-51. PubMed ID: 8018385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda.
    Bruce C; Clegg C; Featherstone A; Smith J; Biryahawaho B; Downing R; Oram J
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1543-50. PubMed ID: 7888209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between anti-V3 peptide and neutralizing antibodies in plasma from HIV-1 infected individuals resident in Brazil.
    Bongertz V; Morgado MG; Galvão-Castro B; Wigzell H; Hendry RM
    Mem Inst Oswaldo Cruz; 1994; 89(1):113-4. PubMed ID: 7823807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographical distribution of HIV-1 group O viruses in Africa.
    Peeters M; Gueye A; Mboup S; Bibollet-Ruche F; Ekaza E; Mulanga C; Ouedrago R; Gandji R; Mpele P; Dibanga G; Koumare B; Saidou M; Esu-Williams E; Lombart JP; Badombena W; Luo N; Vanden Haesevelde M; Delaporte E
    AIDS; 1997 Mar; 11(4):493-8. PubMed ID: 9084797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.